Stock NXTC NEXTCURE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News NextCure, Inc.

Equities

NXTC

US65343E1082

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.35 USD +4.65% Intraday chart for NextCure, Inc. -15.62% +18.42%
Apr. 08 NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024 CI
Apr. 04 NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
GL
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
GL
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024
CI
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
GL
NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board
CI
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
GL
NextCure : March 2024 Corporate Presentation
PU
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
GL
North American Morning Briefing : Markets on Hold -2-
DJ
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
GL
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
AQ
Top Premarket Decliners
MT
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
GL
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
CI
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
GL
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
AQ
Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
CI
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)
AQ
NextCure Provides Year-End Clinical Pipeline Updates
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NXTC Stock
  4. News NextCure, Inc.